Outcomes of prolonged support on surgically implanted microaxial left ventricular assist devices for refractory cardiogenic shock
Extended Impella 5.5 device support beyond 14 days was not associated with increased incidence of mortality, major bleeding, or stroke in our study, and may be effective for patients requiring extended ventricular assist device support as bridge to heart transplant.
Authors
- J. Fried (ORCID: https://orcid.org/0000-0001-6146-2637)
- H. Carmen
- Yuji Kaku (ORCID: https://orcid.org/0000-0002-1366-1129)
- Koji Takeda (ORCID: https://orcid.org/0000-0001-8263-1911)
- Joyce Wald (ORCID: https://orcid.org/0000-0003-0276-3709)
- Gabriel Dardik (ORCID: https://orcid.org/0000-0003-1218-1286)
- Yanling Zhao (ORCID: https://orcid.org/0009-0008-6288-2332)
- Mauer Biscotti (ORCID: https://orcid.org/0009-0002-8071-6625)
- John DePaolo
- Marisa Cevasco (ORCID: https://orcid.org/0000-0002-0075-2574)
- Iris Feng (ORCID: https://orcid.org/0000-0002-6494-126X)
Institutions
- Columbia University Irving Medical Center (US)
- Hospital of the University of Pennsylvania (US)
Publication Details
- Journal
- JTCVS Open
- Published
- 2025-05-02
- DOI
- https://doi.org/10.1016/j.xjon.2025.03.023
- Citations
- 2
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 1.35